On December 8, 2023, the 8th "Maker China" Beijing SME Innovation and Entrepreneurship Competition, also known as the "Maker Beijing 2023" Innovation and Entrepreneurship Competition, jointly organized by the Beijing Municipal Bureau of Economy and Information Technology and the Beijing Municipal Bureau of Finance, successfully concluded. AccuMedical Beijing Ltd.'s "Flow Diverter" project won Second Prize in the Pharmaceutical and Healthcare Industry Category and also secured Third Prize in the Shunyi District-level competition of "Maker Beijing 2023."
Image: Announcement of the Top 10 Projects in the Eight Major Industries of "Maker Beijing 2023"
The "Maker Beijing" competition is a significant brand event aimed at driving SME innovation and entrepreneurship while facilitating industry-finance collaboration. Now in its eighth consecutive year, the competition is jointly organized by the Beijing Municipal Bureau of Economy and Information Technology and the Beijing Municipal Bureau of Finance. It aligns with Beijing’s positioning as an international science and technology innovation hub, focuses on tackling key core technologies, and fosters synergy between innovation and industrial development, stimulating the intrinsic innovation momentum of tech enterprises. Su Guobin, a member of the Party Leadership Group and Deputy Director of the Beijing Municipal Bureau of Economy and Information Technology, stated that hosting the "Maker Beijing" competition is a key initiative to help SMEs integrate resources and drive innovation. In recent years, Beijing has actively implemented the central government’s policies supporting SME development, leveraging technological empowerment, fostering exemplary enterprises, and optimizing the service ecosystem. These efforts have significantly promoted SME growth. Moving forward, Beijing will continue to enhance the allocation of resources, including talent and funding, using the competition as a platform to encourage industry-academia-research collaboration, facilitate the integration of enterprises of different scales, improve service capabilities, and expand brand influence.
As a technology-driven enterprise in the medical device sector, AccuMedical stood out in this year’s competition with its "Flow Diverter" project, demonstrating the company’s commitment to core technology and independent innovation. This achievement further highlights AccuMedical’s leading role in driving innovation in the field of neurointervention. The award-winning project focuses on the treatment of hemorrhagic cerebrovascular diseases and offers innovative clinical solutions. As an urgently needed medical device, it has already been applied in clinical practice, showcasing its effectiveness and impact.
Image: AccuMedical's "Maker Beijing 2023" Trophy and Certificate
Founded in 2017, AccuMedical Beijing Ltd. is an innovative medical device company specializing in the field of neurointervention. Headquartered in Beijing with dual R&D centers in China and the United States, AccuMedical has developed comprehensive businesses including R&D, production, and marketing of neurointerventional devices for the treatment of hemorrhagic and ischemic strokes. Our mission is to offer a whole set of innovative solutions to a global population of cerebrovascular disease patients and physicians. Since its inception, AccuMedical has been dedicated to breakthroughs and advancements in key technologies and processes, focusing on high-barrier, high-clinical-value neurointervention products. As of December 2023, the company has filed over 88 patents, with 43 already granted, including multiple world-first technologies.
The interventional treatment of intracranial aneurysms has entered the era of Flow Diverters (FD). Unlike traditional coil embolization within an aneurysm sac, FDs work by altering blood flow within the parent artery and reconstructing the vascular structure. This reduces the direct impact of blood flow on the aneurysm, leading to blood stagnation and thrombus formation within the aneurysm sac. Moreover, new endothelial cells grow over the surface of the FD at the aneurysm neck, eventually achieving complete aneurysm occlusion while reducing the risk of recurrence. According to the "Chinese Guidelines for Flow Diverter Treatment of Intracranial Aneurysms", FD treatment is highly effective and safe for unruptured wide-neck aneurysms in the internal carotid artery, including small, medium, large, and giant aneurysms. It is rated as a Class I recommendation with Level B evidence. AccuMedical’s Lattice Flow Diverter is currently the most widely approved FD in China, covering both anterior and posterior circulations. It is indicated for treating large/giant, medium, and small aneurysms, as well as saccular and fusiform aneurysms. This extensive applicability allows AccuMedical to offer broader treatment options for patients and address a wider range of cerebrovascular conditions.